← Home / Immunovant, Inc. (IMVT)
Stock Analysis

Immunovant, Inc. (IMVT)

IMVT
IMVT · Healthcare • Biotechnology
43.93 +0.94%
Track IMVT in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when IMVT price is:
52W Range Position
97%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-26 23:21 UTC
WOI Investment Thesis
Constructive
Watch confirmation and structural levels before acting.
⚖️
✓
Fundamentals
Negative / Pressured / Strong
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
No reliable structural support level is currently available.
Not available
↗
Break Above
No setup-specific trigger is available; nearest structural resistance is shown.
45.35
🎯
Next Objective
No defined objective is currently available for the primary technical setup.
Not available
×
Thesis Break
No setup-specific invalidation level is currently defined.
Not available
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
6
●
Financial Results
HIGH
IMVT reports financial results
On August 6, 2026, Immunovant, Inc.
8-K Filing • SEC EDGAR
MAY
20
●
Financial Results
HIGH
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
• IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 • IMVT-1402 proof-...
8-K Filing • SEC EDGAR
What's Driving IMVT?
• No active technical setup
Momentum is Neutral. No qualified technical setup is currently active.
◆ Business quality is mixed
Profitability is negative. Cash generation is pressured. Balance-sheet quality is strong.
Full Analysis Workspace
Technical Signal
No Active Technical Setup
•
No qualified technical setup is currently active.
RSI(14)
64.7
Price Chart
IMVT — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-25
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$8.9B
Company size
EV
$8.4B
Debt-adjusted value
P/B
12.2
Premium
P/FCF
-37.5
Not meaningful
FCF Yield
-2.67%
Cash return
Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Mixed
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
📈 Net Income
-153.22M
↘ Negative
🧮 EPS (Basic)
-0.75
↘ Negative
Immunovant, Inc.
Healthcare • Biotechnology
You Might Also Like